Clinical trial · Interventional
Intervention Study of Drugs in Patients Osteopenia and Osteoporosis
Intervention Study of Different Anti-osteoporpsis Intervention Strategies in Patients With Osteopenia and Osteoporosis
NCT04719572CI-TRIAL-00049596unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a 12 months, randomized, multicenter, open-label, parallel-group study in postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China to evaluate the efficacy and safety of different anti-osteoporpsis intervention strategies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteopenia, Osteoporosis | — | UNRESOLVED | — |
| Osteoporosis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Basic treatment+ anti-osteoporosis drug group | Other | — | UNRESOLVED |
| Basic treatment group | Other | — | UNRESOLVED |
| Basic treatment + non-drug treatment group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Basic treatment group
- description
- elemental calcium 600mg/ day + vitamin D 1000IU/day
- interventionNames
- Other: Basic treatment+ anti-osteoporosis drug group
- Other: Basic treatment + non-drug treatment group
- type
- ACTIVE_COMPARATOR
- label
- Basic treatment+ anti-osteoporosis drug group
- description
- alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition
- interventionNames
- Other: Basic treatment group
- Other: Basic treatment + non-drug treatment group
- type
- OTHER
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Informed consent obtained before any trial-related activities * Postmenopausal women and male aged 50 years or old * Osteoporosis by DXA or fragility fracture history * Osteopenia with more than one osteoporotic risk factors Exclusion Criteria: * Secondary osteoporosis * Renal insufficiency (Ccr\< 35ml/min) * New fractures \< 3 months, prior bilateral hip fractures or surgical replacement. * Other medication contraindications * Malignant tumors * Mobility-impaired individuals
References
Publications (0)
Data not yet available
No reference posted for this study.